A Europe-wide Strategy to enhance Transplantation of highly sensitized patients on basis of Acceptable HLA Mismatches

Provider

Ministry of Education, Youth and Sports

Programme

—

Call for proposals

FP7-HEALTH-2012-INNOVATION-1

Main participants

Institut klinické a experimentální medicíny

Contest type

RP - Co-financing of EC programme

Contract ID

MSMT-42111/2013

Project name in Czech

A Europe-wide Strategy to enhance Transplantation of highly sensitized patients on basis of Acceptable HLA Mismatches

Annotation in Czech

The presence of donor specific HLA antibodies is a contra-indication for renal transplantation. Highly sensitized patients accumulate and often die on the transplant waiting lists as it is almost impossible to find donors towards which they don?t have antibodies. The acceptable mismatch program of Eurotransplant has shown to be an effective tool to enhance successful transplantation of highly sensitized patients. However, 35% of the patients have rare HLA phenotypes and no suitable donor can be found. HLA phenotype frequencies vary amongst European populations. Rare HLA phenotypes in one population are more frequent in other populations. The major objective of the 11 partners in this project is to analyze the feasibility and requirements for a Europe-wide acceptable mismatch program to enhance transplantation of patients with rare HLA phenotypes in their own population. Long waiting patients will be matched with virtual donors based on known HLA frequencies of different European populations and with actual donors from the different transplant organizations. If successful, the logistics will be tested by transplanting some of these patients with donors from elsewhere in Europe. Second objective is to simplify the definition of acceptable HLA mismatches. Although almost 4000 HLA class I antigens are known, only 150 polymorphic residues differentially spread over the different HLA antigens are responsible for the induction of antibodies. An innovative typing and matching strategy based on the definition of acceptable HLA epitopes will facilitate the identification of suitable donors. Third objective is to define whether antibodies against non-HLA targets on the donor endothelium affect the results of transplants in highly sensitized patients. The aimsof this collaborative project are fully compatible with those required for the program Health.2012.1.4-1. In objectives 2 and 3 two partners belonging to the SME sector of the European industry are involved.

R&D category

AP - Applied research

CEP classification - main branch

FN - Epidemiology, infection diseases and clinical immunology

CEP - secondary branch

FJ - Surgery including transplantology

CEP - another secondary branch

—

OECD FORD - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)

30212 - Surgery<br>30213 - Transplantation<br>30302 - Epidemiology<br>30303 - Infectious Diseases

Provider evaluation

U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)

Project results evaluation

Following the condition that the candidate of financial contribution was evaluated and afterwards selected by international provider in accordance with the rules of the program the Ministry of Education, Youth ans Sports does not realize the evaluation of project results. The project is evaluated only after its approval by an international provider.

Realization period - beginning

Jan 1, 2013

Realization period - end

Nov 30, 2015

Project status

U - Finished project

Latest support payment

Mar 20, 2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data delivery code

CEP16-MSM-7E-U/01:1

Data delivery date

Oct 6, 2017

Total approved costs

1,281 thou. CZK

Public financial support

1,281 thou. CZK

Other public sources

0 thou. CZK

Non public and foreign sources

0 thou. CZK